Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2005-01-12
2009-10-27
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S179100, C530S391500
Reexamination Certificate
active
07608241
ABSTRACT:
Antibody binding assays and radiolabeling kits are disclosed for radiolabeling and testing therapeutic antibodies in the commercial setting. In particular, the kits are designed for making and evaluating radiolabeled anti-CD20 conjugates to be used for the treatment and imaging of B cell lymphoma tumors. All kit reagents are sterile and are designed to achieve a high level of antibody radiolabeling and product stability with results which are highly reproducible.
REFERENCES:
patent: 3994966 (1976-11-01), Sundberg et al.
patent: 4043998 (1977-08-01), Meares et al.
patent: 4315851 (1982-02-01), Yoshikumi et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4348376 (1982-09-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4401592 (1983-08-01), Yoshikumi et al.
patent: 4444744 (1984-04-01), Goldenberg
patent: 4454106 (1984-06-01), Gansow et al.
patent: 4460559 (1984-07-01), Goldenberg
patent: 4460561 (1984-07-01), Goldenberg
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4622420 (1986-11-01), Meares et al.
patent: 4636380 (1987-01-01), Wong
patent: 4707352 (1987-11-01), Stavrianopoulos
patent: 4722892 (1988-02-01), Meares et al.
patent: 4735210 (1988-04-01), Goldenberg
patent: 4767609 (1988-08-01), Stavrianpoulos
patent: 4816567 (1989-03-01), Cabilly
patent: 4824986 (1989-04-01), Gansow et al.
patent: 4831175 (1989-05-01), Gansow et al.
patent: 4855353 (1989-08-01), Kurami et al.
patent: 4861579 (1989-08-01), Meyer, Jr. et al.
patent: 4921690 (1990-05-01), Beatty et al.
patent: 4923985 (1990-05-01), Gansow et al.
patent: 5009069 (1991-04-01), Molini
patent: 5034223 (1991-07-01), Abrams et al.
patent: 5059518 (1991-10-01), Kortright et al.
patent: 5101827 (1992-04-01), Goldenberg
patent: 5124471 (1992-06-01), Gansow et al.
patent: 5130118 (1992-07-01), Johnson et al.
patent: 5162115 (1992-11-01), Pietronigro
patent: 5208008 (1993-05-01), Ranadive et al.
patent: 5217704 (1993-06-01), Johnson et al.
patent: 5219556 (1993-06-01), Wolfangel
patent: 5246692 (1993-09-01), Gansow et al.
patent: 5286850 (1994-02-01), Gansoh et al.
patent: 5363846 (1994-11-01), Rubin et al.
patent: 5376356 (1994-12-01), Morgan, Jr.
patent: 5403573 (1995-04-01), Day et al.
patent: 5428154 (1995-06-01), Gansow et al.
patent: 5434287 (1995-07-01), Gansow et al.
patent: 5460785 (1995-10-01), Rhodes et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5541287 (1996-07-01), Yau et al.
patent: 5545403 (1996-08-01), Page
patent: 5545405 (1996-08-01), Page
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5620675 (1997-04-01), McBride et al.
patent: 5641637 (1997-06-01), Hudak et al.
patent: 5650134 (1997-07-01), Albert et al.
patent: 5698178 (1997-12-01), Goldenberg
patent: 5728369 (1998-03-01), Griffiths
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5766571 (1998-06-01), Ceriani et al.
patent: 5820845 (1998-10-01), Dean et al.
patent: 5830431 (1998-11-01), Srinivasan et al.
patent: 5874540 (1999-02-01), Hansen et al.
patent: 5942210 (1999-08-01), Ultee et al.
patent: 5976492 (1999-11-01), Griffiths et al.
patent: 6010680 (2000-01-01), Govindan et al.
patent: 6994840 (2006-02-01), Chinn
patent: 0 274 394 (1988-07-01), None
patent: 0315188 (1989-05-01), None
patent: 0 529 645 (1993-03-01), None
patent: WO 88/04936 (1988-07-01), None
patent: WO 92/07466 (1992-05-01), None
patent: WO 94/11026 (1994-05-01), None
patent: WO 96/14879 (1996-05-01), None
Goodwin, D A, et al, Jour. Nucl. Med., 26, 493-502, 1985.
Adams RA, “Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma,”Cancer Research, 1967, 27(1):2479-2482.
Adams RA, et al., “Direct implantation and transplantation of human acute lymphoblastic leukemia in hamsters,” 1968,Cancer Research, 28:1121-1125.
Antisoma, Internet reference, 16 pp.
Applebaum, “Radiolabled Monoclonal Antibodies in Treatment of NHL,” Hematology/Oncology Clinics of North America 5(5):1013-1025 (1991).
Brechbiel et al., “Synthesis of 1-(p-Isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies,”Inorganic Chemistry, 1986, 25(16):2772-81.
Brechbiel et al., “Synthesis of C-Functionalized trans-Cyclohexyldiethylenetriaminepenta-acetic Acids for Labelling . . . Emitter,” J. Chem. Soc. Perkin Trans., 1173-1178, 1992.
Chakrabarti et al., “Prevention of radiolysis of monoclonal antibody during labeling,” 1996, J. Nucl. Med., 37:1384-88.
Chinol et al., “Generator-Produced Yttrium-90 for Radioimmunotherapy,” J. Nucl. Med. 28(9):1465-1470 (1987).
Cytogen, Internet reference, 15 pp.
DeNardo et al., “Yttrium-90/Indium-111 DOTA peptide chimeric L6: pharmacokinetics, dosimetry and initial therapeutic studies in patients with breast cancer,” J. Nucl. Med., 1995, 36:97P.
Gansow et al., “Advanced Methods for Radiolabeling Monoclonal Antibodies with Therapeutic Radionuclides,”Cancer Therapy With Radiolabelled Antibodies, 1995, Chapter 6, pp. 63-76.
Gansow et al., “Macrocyclic or Conventional Ligands? Selection of Effective Chelators . . . Radioimmunotherapy,” Chem. Sect., Radiation Oncol. Branch, Natl. Canc. Inst.
Griffiths, GL, “Antibody Radiolabeling With Isotopes of Rhenium,”Cancer Therapy With Radiolabelled Antibodies, 1995, Chapter 7, pp. 77-86.
Griffiths et al., “Rapid, facile and quantitative radiolabeling of DOTA-hMAb conjugates with Y-90 cancer radioimmunotherapy,” Abstract from AACR Meeting, Noa. 4242.
Grossbard et al., “Monoclonal Antibody-Based Therapies of Leukemia and Lymphoma,” Blood 80(4):863-876 (1992).
Hird et al., “Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody,” Br. J. Cancer, 68:403-406, 1993.
Hnatowich et al., “The Preparation of DTPA-Coupled Antibodies Radiolabeled with Metallic Radionuclides: an Improved Method,” J. Immun. Meth. 65:147-157 (1983).
Huneke et al., “Effective α-Particle-mediated Radioimmunotherapy of Murine Leukimia1,” Cancer Research, 52:581-5820, 1992.
Izard et al., “An Imiproved Method for Labelling Monoclonal Antibodies with Samarium-153: Use of the Bifunctional Chelate . . . Acid,” Bioconjugate Chem., 3(4), 346-350, 1992.
Kaminski et al., “131I Anti-b1: Initial Clinical Evaluation in B Cell Lymphoma,” third Conference on Radioimmunodetection and . . . Cancer, Abstract No. 144, (1990).
Kaminski et al., “Initial Clinical Radioimmunotherapy Results with131I Anti-CD20) in Refractory B cell Lymphoma, Fourth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer Antibody . . . ,I” 5(3) Abstract No. 57.
Kinsey et al., “Efficient Conjugation of DTPA to an IgM Monoclonal Antibody in Ascites Fluid,” Nucl., Med. Biol., 15(3):285-292, 1988.
Kobayashi et al., Pharmacokinetics of In-111 and I-125 labeled anti-Tac single-chain Fv recombinant immunotoxin (LMB2), Abstract from AACR Meeting No. 4239.
Kozak et al., “Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity,”Cancer Research, 1989, 49:2639-44.
Kukis et al., “Optimized Conditions for Chelation of Yttrium-90-DOTA Immunoconjugates,” J. Nucl. Med. 1998, 39:2105-2110.
Larson et al., “Comparison of Bone Marrow Dosimetry and Toxic Effect of High Dose . . . to Man,” Nucl. Med. Biol. 16(2):153-158 (1989).
Leland et al., “Electrogenerated chemilumnescence: An oxidative-reduction type ECL reaction sequence using Tripropyl Amine,”Electrochem. Soc., 1990, 137, 3127.
Lewis et al., “A facile, water-soluble method for modification of proteins with DOTA,” Bioconjugate Chem., 1994, 5:565-76.
Lindmo T., et al., “Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess,”Immunol. Methods, 1984, 72:77-.
Chinn Paul
LaBarre Michael J.
Leonard John E.
Morena Ronald A.
Lerner David Littenberg Krumholz & Mentlik LLP
Rit Oncology, LLC
Saunders David A
LandOfFree
Radiolabeling method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radiolabeling method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiolabeling method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4058256